Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACRV

Acrivon Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$1.74

Up+$0.07 (+4.19%)

Updated Nov 5, 2026, 4:21 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.65M
P/E ratio
-0.71
Dividend yield
0.00%
52-week range
$1.27 – $2.39
Volume
127.89K
Avg. volume
1.62M

Price performance · ACRV

ACRV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

ACRV closed at $1.74 after 21 trading sessions, down 7.45% for the selected period.

Last close
$1.74
Period change
-7.45%
Period low
$1.61
Period high
$1.91
Daily close
View OHLC price history
ACRV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$1.69$1.77$1.65$1.74127.89K
Nov 3, 2026$1.61$1.67$1.61$1.67133.86K
Nov 2, 2026$1.66$1.7072$1.58$1.61228.22K
Oct 30, 2026$1.74$1.76$1.65$1.66165.74K
Oct 29, 2026$1.80$1.85$1.71$1.76110.57K
Oct 28, 2026$1.69$1.79$1.6784$1.79133.37K
Oct 27, 2026$1.73$1.78$1.63$1.74168.54K
Oct 26, 2026$1.74$1.77$1.69$1.72259.13K
Oct 23, 2026$1.76$1.8202$1.68$1.73108.18K
Oct 22, 2026$1.84$1.86$1.72$1.7690.31K
Oct 21, 2026$1.80$1.88$1.80$1.825159.07K
Oct 20, 2026$1.78$1.82$1.75$1.795185.41K
Oct 19, 2026$1.68$1.74$1.63$1.69122.95K
Oct 16, 2026$1.75$1.77$1.63$1.64266.38K
Oct 15, 2026$1.74$1.80$1.71$1.76114.48K
Oct 14, 2026$1.73$1.81$1.70$1.72215.81K
Oct 13, 2026$1.86$1.8721$1.74$1.75477.27K
Oct 12, 2026$1.91$1.9292$1.87$1.90140.65K
Oct 9, 2026$1.88$1.955$1.8624$1.91192.04K
Oct 8, 2026$1.89$1.905$1.78$1.87419.7K
Oct 7, 2026$1.85$1.9133$1.82$1.88283.46K

Latest ACRV news

The latest Smart Investors Daily articles mentioning ACRV.

Stock researchCompany · Overview

ACRV research

Overview

Company profile and research snapshot.

Company profile

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$21.83
Implied upside
—
Analysts
15
ACRV recent ratings
DateFirmRatingTarget
Jan 9, 2026Piper SandlerOverweight—
Nov 25, 2025HC Wainwright & Co.Buy—
Aug 14, 2025OppenheimerOutperform—
May 16, 2025Jones TradingHold—
May 15, 2025OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable clinical activity, including confirmed complete and partial responses (RECIST 1.1) with ACR-2316 monotherapy in heavily pretreated, AP3-predicted tumor types, including endometrial and lung cancers Activity in K-Ras pathway mutated cancers and reported synthetic lethality for WEE1 inhibition in K-Ras

Yahoo · Oct 20, 2026

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors IND-enabling studies ongoing with IND submission on track for first half of 2027 WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnol

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By